Literature DB >> 16484824

Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin.

G Quéreux1, C Volteau, J M N'Guyen, B Dréno.   

Abstract

BACKGROUND: The effectiveness of oral isotretinoin against acne is undeniable. However, few data on the maintenance of effect after treatment termination have been published.
OBJECTIVE: The purpose of the study was to identify the risk factors of relapse after stopping isotretinoin.
METHOD: This prospective open study examined 52 patients with moderate to severe acne at the Dermatological Clinic of the Nantes University Hospital (France). Variables likely to influence relapse were studied using the Cox model.
RESULTS: 27 patients (52%) relapsed after stopping treatment. In multivariate analysis, severe seborrhoea and a high score of inflammatory lesions at the end of the treatment, an early age, a family history of acne, prepubertal acne and acne extended to the trunk were the factors increasing significantly the risk of relapse.
CONCLUSION: Our data allow to define more precisely the profile of acne patients for whom the risk of relapse is highest and who should therefore be followed up quite regularly after treatment termination. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16484824     DOI: 10.1159/000090658

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  9 in total

1.  The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions.

Authors:  James J Leyden; James Q Del Rosso; Eric W Baum
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

Review 2.  Not all acne is acne vulgaris.

Authors:  Harald P Gollnick; Christos C Zouboulis
Journal:  Dtsch Arztebl Int       Date:  2014-04-25       Impact factor: 5.594

3.  [Isotretinoin. How should it be used?].

Authors:  A Thielitz; H Gollnick
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

4.  FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial.

Authors:  Alexandra Poinas; Marie Lemoigne; Sarah Le Naour; Jean-Michel Nguyen; Solène Schirr-Bonnans; Valery-Pierre Riche; Florence Vrignaud; Laurent Machet; Jean-Paul Claudel; Marie-Thérèse Leccia; Ewa Hainaut; Nathalie Beneton; Cécile Dert; Aurélie Boisrobert; Laurent Flet; Anne Chiffoleau; Stéphane Corvec; Amir Khammari; Brigitte Dréno
Journal:  Trials       Date:  2020-06-25       Impact factor: 2.279

Review 5.  Isotretinoin; A review on the Utilization Pattern in Pregnancy.

Authors:  Sajad Khiali; Afshin Gharekhani; Taher Entezari-Maleki
Journal:  Adv Pharm Bull       Date:  2018-08-29

6.  Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology.

Authors:  Ediléia Bagatin; Caroline Sousa Costa; Marco Alexandre Dias da Rocha; Fabíola Rosa Picosse; Cristhine Souza Leão Kamamoto; Rodrigo Pirmez; Mayra Ianhez; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2020-10-03       Impact factor: 1.896

Review 7.  Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review.

Authors:  Yuliya Lytvyn; Katherine McDonald; Asfandyar Mufti; Jennifer Beecker
Journal:  JAAD Int       Date:  2022-02-10

8.  Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin.

Authors:  Małgorzata L Kmieć; Anna Pajor; Grażyna Broniarczyk-Dyła
Journal:  Postepy Dermatol Alergol       Date:  2013-12-18       Impact factor: 1.837

9.  Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin.

Authors:  Alshammari Sa; Alamri Y; Alanazi Am; Almuhanna Sa; Pinjabi L; Alsnaidi Na
Journal:  Saudi Pharm J       Date:  2020-02-10       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.